Fibrosis-Inflammation Lab

⌘K

Fibrosis-Inflammation Lab

検証済みの前臨床モデルと専門的なインサイトを通じて、線維化・炎症研究を加速します。

リサーチ

モデル
薬剤
インサイト
リソース
シグナル経路

企業情報

編集部について
お問い合わせ
プライバシーポリシー

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

プライバシーポリシー

/

/

Abituzumab (abituzumab) | 加速させる、線維化研究を

Home/Drugs/Abituzumab

Abituzumab

abituzumab

Phase 2a

Sponsor: Merck KGaA

Indication: SSc

Mechanism of Action

Anti-CD146 monoclonal antibody

Target: CD146

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT00958477

A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer

Phase:PHASE1Org:Merck KGaA, Darmstadt, Germany

TERMINATEDNCT02745145

Abituzumab in SSc-ILD

Phase:PHASE2Org:EMD Serono

WITHDRAWNNCT03688230

Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.

Phase:PHASE2Org:SFJ Pharmaceuticals, Inc.

COMPLETEDNCT01008475

EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer

Phase:PHASE1, PHASE2Org:Merck KGaA, Darmstadt, Germany

COMPLETEDNCT01360840

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

Phase:PHASE2Org:EMD Serono

View all trials on ClinicalTrials.gov

Relevant Publications (PubMed)

No recent publications found for abituzumab.

Validated Models

This drug has been validated in the following preclinical models: